IRCT20200131046317N2尚未招募3 期
Evaluation of the effect of thymoquinone in the treatment of infants with infantile refractory spasm
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 4 months 至 18 months（—）
- 性别
- All
入选标准
- •Infants who, despite receiving at least 5 days of injectable corticotropin with at least one other appropriate drug for the treatment of infantile spasm, have at least 3 seizures per week as spasms or myoclonic
- •Parental satisfaction
排除标准
- •having liver or kidney disease.
- •neurodegenerative disease.
研究者
相似试验
招募中
2 期
Evaluation of Efficacy and Safety of Thymoquinone compared to Best supportive care in Patients with COVID-19CTRI/2020/05/025167Intas Pharmaceuticals Ltd
尚未招募
不适用
Black seed as an oral cleansing agentCTRI/2021/04/033045Saima Yunus Khan
撤回
不适用
Analysis of the differential effects of anti thymocyte globulin (ATG) on lymphocyte subsets in patients with severe aplastic anemiasevere aplastic anemia10002086acquired aplastic anemiaNL-OMON42742eids Universitair Medisch Centrum30
进行中（未招募）
1 期
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyEUCTR2020-002100-39-FRPTC THERAPEUTICS, INC.80
进行中（未招募）
1 期
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyGenetically determined mitochondrial disease and associated refractory epilepsyMedDRA version: 20.0Level: LLTClassification code 10077953Term: Refractory epilepsySystem Organ Class: 100000004852MedDRA version: 20.0Level: HLTClassification code 10052637Term: Genetic mitochondrial abnormalities NECSystem Organ Class: 100000004850EUCTR2020-002100-39-PLPTC THERAPEUTICS, INC.80